What are the potential biases that can be introduced during an open-label extension?

Jun 7, 2021 ... To determine the efficacy of oral immunotherapy (OIT) with raw egg white powder and study its effects on humoral responses in children with persistent egg ... Acthar® Gel (repository corticotropin injection) is FDA-approved for treatment of acute episodes or exacerbation of PsA, but no clinical trials have ... Nov 2, 2023 ... Interim Analyses from the Beacon Trial: A Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria. Gayle Ross ... Search Clinical Trials ; GOG-3112 (DESTINY-Ovarian01) · A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus ... Jan 4, 2024 ... Participants were randomly assigned to treatment with the glucagon-like peptide 1 receptor agonist semaglutide or the sodium–glucose cotransporter 2 inhibitor ... Jun 17, 2023 ... Treatment with amikacin liposome inhalation suspension (ALIS) improve culture conversion in patients with M abscessus pulmonary disease. Knowledge on rare diseases and orphan drugs · Search for a clinical trial · A Phase 2 Randomized, Open-Label Trial of PA-824-Containing Regimens Versus Standard ... May 2, 2023 ... A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin ... May 29, 2024 ... Infusion of mbIL-7-TIL has acceptable safety and potent efficacy in recurrent OC patients who have limited treatment options. Mar 4, 2025 ... Inclusion Criteria: ... Unresponsive to ≥2 courses of Bacillus Calmette-Guerin (BCG) therapy within the last 12 months. BCG-unresponsive refers to ...